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Abstract 
Background: Microvessel count (MVC) was correlated with patient prognosis in 
hepatocellular carcinoma. We investigate whether the MVC using CD34 antibody was 
associated with the disease-free and overall survival in metastatic liver cancer (MLC) 
patients. 
Methods: We examined relationships between MVC and clinicopathological factors or 
postoperative outcomes in 139 MLC patients who underwent hepatectomy between 
1990 and 2006. CD34 expression was analyzed by the immunohistochemical method. 
Results: MVC was associated with the fibrous pseudo-capsular formation by the 
histological examination. Using the modern Japanese classification of liver metastasis, 
poorer survival was associated with higher score, poorly differentiated adenocarcinoma, 
higher preoperative CEA level, fibrous pseudo-capsular formation and shorter surgical 
margin. Decreased disease-free survival was associated with higher score using the 
Japanese classification of liver metastasis, multiple or bi-lobar tumor, regional lymph 
node metastasis in primary colon carcinoma, preoperative CEA level, fibrous 
pseudo-capsular formation and shorter surgical margin (<5 mm). Higher MVC 
(≥406/mm2) was associated with decreased disease-free and overall survival by 
univariate analysis (P = 0.034 and P = 0.021, respectively) and lower MVC represented 
an independent prognostic factor in overall survival by Cox’s multivariate analysis (risk 
ratio, 2.71; P = 0.023), in addition to histological differentiation.  
Conclusion: Tumor MVC appears to be a useful prognostic marker of MLC patient 
survival. 
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Synopsis 
Tumor microvessel count by immunohistochemical staining using CD34 antibody is a 
useful prognostic marker of overall survival in metastatic liver carcinoma patients who 
underwent hepatectomy. 
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Hepatic resection is a useful option in the radical treatment of metastatic liver 
carcinoma (MLC). However, recurrence rates after resection remain high limiting 
patient survival.1, 2 Some clinicopathological factors in MLC, specifically, tumor 
recurrence and tumor biological characteristics, provide useful information regarding 
tumor activity.3-5 According to previous reports, good potential candidates for molecular 
markers and tumor biological factors in MLC patients include lymphatic microvessel 
density (MVD) using CD31 antibody,7 doubling times, 8 angiogenic factors, 9 growth 
factors,10 abnormal expression of other oncogenes and suppressor genes such as TP53, 6 
and carcinoembryonic antigen.11 The use of a combination of conventional 
clinicopathological factors and tumor biology may improve our prognostic ability in 
patients who undergo hepatectomy for MLC and may contribute to a better staging 
system. 
Tumor angiogenesis may be important in supporting tumor growth.12 Metastatic 
liver cancer also expresses angiogenic factors such as vascular endothelial growth factor 
(VEGF) and microvessel counts. 9, 13 Levels of these angiogenic factors may affect 
patient survival. 9, 13 Recent studies have shown that microvessel density (MVD) in 
MLC correlates with tumor aggressiveness and prognosis. 13 Using multivariate analysis, 
we have already shown that higher microvessel count (MVC) using CD34 antibody is 
independently associated with poorer prognosis in MLC patients undergoing hepatic 
resection.14, 15 Based on this prior work, we hypothesize that hypervascularity is a 
prognostic indicator of decreased survival in patients with MLC, since it is associated 
with tumor growth and invasion. 
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MATERIALS AND METHODS 
Patients 
MLC specimens from 139 patients (93 men, 46 women) were excised during 
surgery performed on patients admitted to the Division of Surgical Oncology at 
Nagasaki University Graduate School of Biomedical Sciences (NUGSBS) between 
1990 and 2006. The mean age for patients at the time of surgery was 62.6 ± 12.3 years 
(range, 24 - 85 years). Primary cancers included colon carcinomas in 75 patients and 
rectal carcinomas in 64 patients. 
Patients with simultaneous liver metastasis who underwent resection of both the 
primary lesion and hepatectomy numbered 62 (45%). 136 patients had a Child-Pugh 
classification of A and 3 patients (2%) had a Child-Pugh classification of B. The 
operative procedures included hemihepatectomy or extended hemihepatectomy (n = 22), 
segmentectomy or sectionectomy (n = 85) and partial resection (n = 32). Radical 
hepatectomy was performed to remove hepatic tumor without leaving any residual 
tumor. All hepatic tumors were completely resected without macroscopic exposure of 
the amputated section to the remaining liver. 
Patients undergoing additional ablation therapy were excluded from our series. All 
in-hospital deaths were excluded and only cancer-related death was included in our 
study. The minimum follow-up period after hepatic resection of HCC was 22 months. 
We used the classification system of the General Rules for the Clinical and 
Pathological Studies on Cancer of the Colon, Rectum and Anus by the Japanese Society 
for Cancer of the Colon and Rectum for clinicopathological evaluation 16 and the H 
classification of Japan to evaluate the stage of liver metastasis (Table 1). 16 All study 
protocols were approved by the Human Ethics Review Board of our institution. 
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Informed consent for data collection was obtained from each patient during this period. 
Anesthesia data and patient data were retrieved from the NUGSBS database. 
 
Immunohistochemical staining 
Resected specimens were fixed in 10% formalin and embedded in paraffin. Thin 
sections (4 μm) were deparaffinized twice using xylene and rehydrated in a series of 
ethanol solutions (100%, 90% and 80%). Sections were placed in 0.01 mol/L trisodium 
citrate dehydrate buffer (pH 6.0) and treated in a microwave oven for 10 min at 500 W. 
For CD34 staining, 14, 15 tissue sections were digested with 0.2% trypsin in 0.01 
mol/L phosphate-buffered saline (PBS) for 20 min at 37 °C. The tissues were then 
immersed in 3% H2O2 with distilled water for 10 min to inactivate endogenous 
peroxidases. After blocking non-specific binding by normal goat serum, sections were 
incubated overnight at 4°C with mouse anti-monoclonal CD34 antibody (1:25; 
QB-END/10, Novocastra Laboratories, Newcastle, United Kingdom) as the primary 
antibody. This was followed by reaction with biotinylated anti-immunoglobulin and 
reagent using labeled streptavidinbiotin (LSAB) kit peroxidase (Dako, Carpinteria, CA). 
The peroxidase reaction was visualized with 0.01% H2O2 and 3, 3’-diaminobenzidine 
under light microscopy (×200). For MVC using CD34 staining, average count was 
determined in the 5 most-vascular areas in the HCC examined at 200× magnification. 14, 
15 Two pathologists blindly assessed each slide. 
 
Statistical analysis 
Continuous data were expressed as mean ± standard deviation. Data from different 
groups were compared using one-way analysis of variance (ANOVA) and examined by 
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Student’s t-test or Dunnett’s multiple comparison test. For univariate analysis, 
categorical data were analyzed using Fisher’s exact test. Disease-free and overall 
survival rates were calculated according to the Kaplan-Meier method, and differences 
between groups were tested for significance using the log-rank test. Multivariate 
analysis was performed using proportional Cox’s hazards regression modeling. A 
two-tailed value of P < 0.05 was considered statistically significant. All statistical 
analyses were performed using SAS software (Statistical Analysis System, Cary, NC). 
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RESULTS 
Among the 139 patients in the present study, overall 1-, 3-and 5-year survival rates 
were 76%, 48% and 36%, respectively, and median overall survival was 65 months. 
Disease-free 1-, 3-and 5-year survival rates were 45%, 19% and 14%, respectively, and 
median disease-free survival was 29 months. Of 100 patients (71.9%) who displayed 
tumor recurrence after hepatectomy, 21 (15.1%) received re-hepatectomy and 79 
(56.8%) received chemotherapy. Median MVC within the tumor area was 238/mm2, and 
this value was applied as the cut-off value. 
Table 2 shows the relationship between microvessel count and clinicopathological 
features. MVC was significantly higher in tumors with fibrous pseudo-capsule 
formation compared to those tumors without this capsule. However, MVC was not 
associated with any other clinicopathological factor, H classification or postoperative 
recurrence rate. 
Table 3 shows the relationship between disease-free or overall survival and 
clinicopathological factors including microvessel count. Preoperative carcinoembryonic 
antigen (CEA) level, H classification, number of tumors, tumor distribution and 
microvessel count were related to disease-free survival. H classification, histological 
differentiation, fibrous pseudo-capsule formation, surgical margin and MVC were 
associated with overall survival and this result was statistically significant. Fig. 1 shows 
disease-free and overall survival after hepatectomy compared to microvessel count. 
Disease-free survival rate was significantly lower in patients with higher microvessel 
count compared to patients with lower MVC using a cut-off level of 409/mm2. Overall 
survival rates were also significantly lower in patients with higher MVC. 
Table 4 shows the results of multivariate analysis for disease-free and overall survival 
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after hepatectomy for various factors that showed significant association on univariate 
analysis. A higher level of preoperative CEA level was associated with lower 
disease-free survival after hepatectomy but this finding was not significant. On the other 
hand, poorly differentiated adenocarcinoma and higher microvessel density were 




Nanashima et al. 
DISCUSSION 
Tumor angiogenesis is closely associated with tumor aggressiveness and poorer 
prognosis in patients with primary liver tumors14, 15 and, therefore, this biological 
characteristic appears essential to hepatic tumor progression. Preliminary results from 
our study and other studies reveal that tumor angiogenesis has a significant impact on 
prognosis in patients with metastatic liver cancer who undergo radical hepatectomy. In 
addition, the tumor hypervascularity is associated with lower patient survival rates. 16, 17 
Various angiogenic factors such as VEGF, Flk-1/KDR and flt-1 closely reflect tumor 
angiogenesis.7, 9, 18 Tumor angiogenesis, can also be easily examined using 
immunohistochemistry and, therefore, we propose its use in the pathologic evaluation of 
hepatic tumors. 
From our clinical experience, metastatic liver cancer sometimes shows 
hypervascularity by the enhanced computed tomography or angiography and we 
examined the relationship between the tumor enhancement pattern using computed 
tomography and MVC and, however, we could not find any relationship between these 
two parameters by the preliminary data (not published yet). We originally hypothesized 
that there was a relationship between MVC, vascularity, and histological differentiation 
because previous studies showed a correlation between tumor angiogenesis and depth of 
invasion, lymphatic infiltration and lymph node metastasis in colorectal carcinoma 
patients with liver metastasis.19, 20 Our results showed, however, that MVC was not 
associated with any clinicopathological parameters of metastatic liver cancer and the 
meaning of increased microvessel count, at the biologic level, is still unknown at this 
stage. Although we also examined the significance of MVC in the intrahepatic 
cholangiocarcinomas, which have a similar morphology to MLC, no relationship with 
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pathological characteristics or patient prognosis after surgery was found. 21 
Based on our preliminary data, we focused on the association between MVC and 
post-hepatectomy outcomes and, therefore, we continued to add patients to the study 
and prolonged the follow-up period for these patients. In our analysis of survival, 
several associated tumor parameters, including microvessel count, were revealed upon 
review of the surgical records and these findings are in agreement with previous 
reports.3-13, 17 
Since 1978, factors predictive of patient prognosis have been proposed by many 
investigators (see Table 5). 22-30 However, any consensuses have yet to be achieved at 
this stage. As shown in both our preliminary data and our final results, higher 
microvessel count is associated with shorter disease-free periods and shorter overall 
survival times in patients with metastatic liver cancer undergoing hepatectomy. 17, 18 The 
multivariate analysis for patient prognosis, however, showed that only the preoperative 
CEA level was associated with disease-free survival, however this result was not 
significant. No factors including MVC were considered independent risk factors of 
tumor-free survivals in the present study. 
Previous reports showed that candidate factors associated with recurrence of MLC 
included intrahepatic lymphatic invasion, fibrous capsule formation and oncogenes.31-33 
In a previous report, higher microvessel count was found to be independently associated 
with poorer prognosis.34 MVC would seem to be a useful predictive marker for patient 
survival after hepatectomy. Tumor vascularity may be correlated with proliferative 
activity or invasiveness of MLC. We plan to investigate this further as part of our future 
research. 
Based on future studies using longer follow-up periods, we plant to consider 
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additional anti-angiogenic treatment after hepatectomy. At this stage, some 
anti-angiogenic drugs, including bevacizumab for colorectal liver carcinoma, have been 
developed 35, 36 and applied in the clinical setting.37, 38 In cases were tumor angiogenesis 
is strongly associated with patient survival, anti-angiogenic drugs could be used more 
aggressively. Based on our present findings, we hope to examine the survival benefit of 
adjuvant bevacizumab chemotherapy after radical hepatectomy to clarify the efficacy of 
MVC. MVC may become a selection marker in determining the need for adjuvant 
chemotherapy using anti-angiogenic drugs. 
In conclusion, we have demonstrated that higher microvessel count, as identified by 
CD34 antibody levels in metastatic liver cancer patients, is an independent predictor of 
overall survival in these patients. As a tumor biological factor, MVC (representing 
tumor angiogenesis) appears to be a practical alternative for predicting tumor recurrence 
and survival in patients with metastatic liver cancer. Furthermore, this factor can 
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FIGURE LEGEND 
 
Fig.1. Disease-free and overall survivals after hepatectomy in patients with metastatic 
liver carcinoma compared to microvessel count. Cut-off level of MVC was set at a 
409/mm2. A solid line shows a lower MVC and a dotted line shows a higher MVC.  
TABLE 1.  Definition and criteria used in the original and revised H-number grading 
system for liver metastasis. 
H-number system† 
HX Liver metastasis, unknown 
H0 No liver metastasis 
H1 Some metastases (≤4 lesions) and size of the largest tumor ≤5 cm 
H2 Except H1, H3 
H3 Some metastases (≥5) and size of the largest tumor >5 cm 
 
†; the H-number of General Rules for Clinical and Pathologic studies on Cancer of the 
Colon, Rectum and Anus in 2006 18 
TABLE 2.  Relationship between microvessel density and clinicopathological factors 
in MLC 
 Microvessel count (/mm2) P value 
Gender  
Male/Female 
Age   
>60 y.o/ ≤60 y.o 
Preoperative CEA 
  <15ng/ml/≥15ng/ml 
Node status of primary carcinoma 
  No/Yes 
Time of liver metastasis 
  Synchronous/Metachronous 
Number of tumor 
  Solitary/Multiple 
Location of tumor 
  Unilobar / Bilobar 
H classification 
  H1/H2/H3 
Histological differentiation 
  Well/Moderately/Poorly 
Vascular invasion 
  No/Yes 
Fibrous pseudo-capsular formation
  No/Yes 
Postoperative tumor recurrence 




252±125 / 227±113 
 
219±107 / 220±123 
 
238±105 / 239±119 
 
249±107 / 225±120 
 
224±119 / 242±120 
 
225±105 / 263±131 
 
224±112 / 238±125 / 275±143 
 
200±56 / 238±120 / 300±144 
 
213±138 / 220±118 
 
237±121 / 256±100 
 


























TABLE 3.  Relationship between clinicopathological factors and survival rates in 
MLC 
 Disease-free survival 
rates (5 years:%) 
P value Overall survival 
rates (5 years:%) 
P value 
Gender 
  Male/Female 
Age (years) 
  >60  / ≤60  
Preoperative CEA (ng/ml) 
  >15 / ≤15 
Node status of primary cancer 
  No / Yes 
Time of liver metastasis 
  Simultaneous/Metachronous 
Number of tumor 
1 /  ≥2 
Size of tumor (mm) 
  <50 / ≥50 
Distribution 
  Unilobar / Bilobar 
H classification 
  H1 / H2/ H3 
Histological differentiation 
  Well/Moderately/Poorly 
Vascular invasion 
  No / Yes 
Fibrous pseudo-capsular formation 
  No / Yes 
Microvessel counts, CD34(/mm2) 
  <238  /  ≥238 
Surgical margin (mm) 
  <5  /  ≥5 
Postoperative chemotherapy 
  No / Yes 
 
10 / 16 
 
11 / 17 
 
23 / 10 
 
34 / 8 
 
19 / 8 
 
24 / 6 
 
17 / 13 
 
24 / 6 
 
28 / 0/ 8 
 
18 / 14 / 12 
 
33 / 8 
 
14 / 25 
 
19 / 0 
 
9 / 22 
 
































39 / 36 
 
25 / 42 
 
38 / 31 
 
49 / 30 
 
39 / 33 
 
40 / 34 
 
35 / 41 
 
41 / 28 
 
48 / 21 / 21 
 
47 / 42/ 17 
 
34 / 21 
 
21 / 69 
 
42 / 13 
 
24 / 48 
 































CEA: carcinoembryonic antigen 
TABLE 4. Multivariate analysis by Cox’s proportional hazard test of prognostic factors influencing disease-free survival and overall 
survival in MLC after hepatectomy 
Disease-free survival Overall survival  
Risk ratio 95%CI p Risk ratio 95%CI p 
Node metastasis of primary cancer 
  Positive  vs  negative 
Preoperative CEA level (ng/ml) 
    ≥15  vs  <15 
H classification 
    2,3  vs  1 
Number of tumor 
    ≥2  vs  1 
Distribution of tumor 
    Bilobar  vs  unilobar 
Pathological surgical margin 
    <5mm  vs  ≥5mm 
Fibrous pseudocapsular formation 
    No  vs  Yes 
Pathological differentiation 
    Poorly  vs  well, moderately 
Microvessel counts by CD34 













































































































CEA: Carcinoembryonic antigen 
TABLE 5.  Predictors of tumor recurrence after hepatectomy in metastatic liver cancer reported in previous studies.   
  Primary  Metastasis   
 

























Fortner 1984 22) 
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Nordlinger 1996 24) 
Jaeck 1997 25) 
Cady 1998 26) 
Fong 1999 27) 
Minagawa 2000 28) 
Choti 2002 29) 
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